Pentel P R, Aaron C, Paya C
Int J Obes. 1985;9(2):115-9.
The anorectic agent phenylpropanolamine (PPA) has a low therapeutic index and can cause severe hypertension at doses as low as 85 mg. To determine the effects of a therapeutic dose on blood pressure, PPA 37.5 mg (as a commercially available immediate release formulation) or placebo was administered orally to ten normotensive subjects using a randomized double-blinded crossover design. The mean increase in supine systolic blood pressure (BP) was greater after PPA (18.5 +/- 10.7 mmHg) than after placebo (5.1 +/- 5.4 mmHg, P = 0.005). Increases in systolic BP after PPA ranged from 8 to 43 mmHg. The BP increase due to PPA was postural, and there was no change in sitting or standing BP. Doses of PPA available in over-the-counter formulations can increase supine systolic BP. Recent use of products containing PPA should be considered when evaluating patients with hypertension.
食欲抑制剂去甲麻黄碱（PPA）治疗指数较低，剂量低至85毫克时即可导致严重高血压。为确定治疗剂量对血压的影响，采用随机双盲交叉设计，对10名血压正常的受试者口服37.5毫克PPA（作为市售速释制剂）或安慰剂。服用PPA后仰卧位收缩压（BP）的平均升高幅度（18.5±10.7毫米汞柱）大于服用安慰剂后（5.1±5.4毫米汞柱，P = 0.005）。服用PPA后收缩压升高幅度在8至43毫米汞柱之间。PPA导致的血压升高与体位有关，坐位或站位血压无变化。非处方制剂中的PPA剂量可升高仰卧位收缩压。评估高血压患者时应考虑其近期是否使用过含PPA的产品。
